International Journal of Antimicrobial Agents

Papers
(The H4-Index of International Journal of Antimicrobial Agents is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges3621
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial3237
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality1254
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?714
Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence700
Coronavirus disease 2019 (COVID-19): current status and future perspectives687
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19617
The epidemiology, diagnosis and treatment of COVID-19598
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection418
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies381
Chloroquine for the 2019 novel coronavirus SARS-CoV-2302
Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status255
Arguments in favour of remdesivir for treating SARS-CoV-2 infections239
Increased antimicrobial resistance during the COVID-19 pandemic237
Extra-respiratory manifestations of COVID-19218
Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking195
SARS-CoV-2 was already spreading in France in late December 2019183
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies183
Teicoplanin: an alternative drug for the treatment of COVID-19?182
Procalcitonin levels in COVID-19 patients179
Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein175
Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine158
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update145
Tocilizumab for severe COVID-19: a systematic review and meta-analysis129
COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)126
Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment114
Different mutations in SARS-CoV-2 associate with severe and mild outcome113
Ribavirin therapy for severe COVID-19: a retrospective cohort study112
Lactoferrin as potential preventative and adjunct treatment for COVID-19109
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants96
Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-1995
Drug repositioning is an alternative for the treatment of coronavirus COVID-1986
Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients85
Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-1982
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line81
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study79
A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic79
Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment79
COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies79
Macrolides and viral infections: focus on azithromycin in COVID-19 pathology78
Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal78
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-1977
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal75
Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.10594972
Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors67
Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial67
Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review63
Long-acting drugs and formulations for the treatment and prevention of HIV infection63
Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients58
Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial56
Combating devastating COVID-19 by drug repurposing56
SARS-CoV-2: fear versus data56
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli53
0.036901950836182